Trial Profile

A compassionate use study of Chymotrypsinogen/trypsinogen in patients with advanced metastatic cancers of different origin

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 26 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Chymotrypsinogen/trypsinogen (Primary)
Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer
Focus Adverse reactions; Expanded access

Most Recent Events

22 Feb 2024 Results presented in the Propanc Biopharmas Media Release.
22 Feb 2024 According to a Propanc Biopharmas Media Release, the company to host a conference call to on March 28, 2024, at 2:00 p.m., EST, to discuss results form this trial.
19 Apr 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com